Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...
Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...
Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...
Valneva (VALN) stock rose after the company posted new Phase 3 trial data for its chikungunya vaccine, Ixchiq, in adolescents aged 12-17. Read more here.
Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its ...
Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to ...
In preliminary investigations, the experts have attributed the cluster of at least 73 GBS cases collectively reported by ...
Despite these setbacks, 2022 and 2023 marked a career resurgence for him, leading India to a historic Thomas Cup win and ...
Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.
Samantha Ruth Prabhu shares her journey of recovery from Chikungunya through red light therapy, showcasing her resilience and ...
South sensation Samantha Ruth Prabhu recently opened up about her experience with red light therapy as a treatment for joint ...